The lazy question about a new Buy rating is whether its target is above or below the Street. The question that decides this one is what "a path to positive free cash flow" is worth when the cash flow arrives inside an acquisition and the acquisition arrives on borrowed money.
Brian Gesuale initiated Rocket Lab at Outperform on 11 September with an $80 target, against a Street average of $111 across 19 analysts. His case is positive EBITDA and free cash flow in 2027 and 2028 — two years out, not one — resting on Neutron and on the pending Iridium acquisition, with Rocket Lab becoming the only vertically integrated space company with positive free cash flow once Iridium closes. Press accounts of the note put about $300 million of free cash flow on Iridium.
The $300m is Iridium's own number, and it is struck before the borrowing
That figure is not an estimate of what Rocket Lab can extract. Iridium guided to roughly $318 million of pro forma free cash flow for 2026 and delivered $296 million in 2025, on its own definition. Recurring, published and real, that cash flow is exactly the reason to want the company.
Iridium measures it before the cost of buying Iridium. Rocket Lab's merger prospectus, filed 26 August, prices that cost precisely, and we read it when it landed: a committed 364-day senior secured bridge facility of $3.6 billion, at an effective interest rate of approximately 8.0% as of 30 June, producing pro forma interest of $285,669 thousand for a full year and $141,357 thousand for the June half. A 0.125% move in the rate shifts the annual figure by $4.55 million.
Set the two together and the gap closes to almost nothing. Against Iridium's 2026 guide, $318m less $285.7m leaves $32.3m. Against the $300m in the note, $14.3m.
Same six months, same basis, $31.2 million
One period and one set of filings give the cleanest version. Iridium's own accounts for the six months ended 30 June 2026 show operating cash flow of $185.8m and capital expenditure of $51.8m, so free cash flow of $134.0m. That is after $38.6m of its own net interest — on debt Rocket Lab repays at closing, using bridge proceeds. Add it back to compare like with like and Iridium generated $172.6m before financing. The bridge's pro forma interest for those same six months is $141.4m.
US$m — Iridium's own accounts against Rocket Lab's pro forma
| Six months ended 30 June 2026 | US$m |
|---|---|
| Iridium operating cash flow | 185.8 |
| Capital expenditure | (51.8) |
| Free cash flow | 134.0 |
| Its own net interest, added back | 38.6 |
| Free cash flow before financing | 172.6 |
| Pro forma bridge interest | (141.4) |
| What is left | 31.2 |
Operating cash flow, capital expenditure and net interest are Iridium's reported figures for the six months ended 30 June 2026. Free cash flow is operating cash flow less capital expenditure, our convention, not Iridium's company-defined pro forma free cash flow. The interest add-back approximates cash interest with reported net interest expense, and is ours: it puts Iridium on a pre-financing basis because Rocket Lab repays Iridium's existing debt at closing with bridge proceeds. Bridge interest is the pro forma effective interest amortisation disclosed for the identical six months in the merger prospectus of 26 August 2026.
$172.6m − $141.4m = $31.2m, or about $62m annualised. Three routes, three answers, all in tens of millions rather than hundreds.
The bridge is a placeholder, which is the strongest argument against this
A 364-day facility is not a capital structure, and Rocket Lab has never said it would be. Rocket Lab's own equity prospectus says proceeds "together with any other permanent financing, may be used to reduce the Bridge Commitment or prepay borrowings thereunder". Term it out cheaper and the residual widens: at the disclosed sensitivity, a full point of relief is worth $36.4m a year, and it would take roughly a point and a half to add $55m.
The equity route is priced too, and this is where the tape has the story wrong. The $1,944,369,826 distribution agreement dated 13 August is not fresh authorisation. Rocket Lab replaced a $3 billion programme from 20 May and carried forward what went unsold, and the prospectus says plainly that no additional amount beyond the unsold portion is being offered. What it also discloses, and what we could not answer in August, is the draw: Rocket Lab had sold $1,055,630,173 under the May programme by 13 August, 35% of it in under three months. None of the $1.944bn had been sold on that date, because the $1.944bn is definitionally what had not been. The remaining $1.944bn is 31.4 million shares at the 10 September close of $61.96, 5.2% of the 598,350,482 outstanding at 5 August.
Nothing in the case has flown or closed
Neutron has never flown. Our own model books no Neutron revenue before 2027 Q3 and no Iridium revenue before then either, which is what a mid-2027 close implies. Electron is the part that works — 16 launches through 11 September, the 95th mission overall, about 1.9 a month — and it is the smaller half. Launch Services booked $44.6m of last quarter's $234.1m, down from $46.6m a year earlier, against $189.5m for Space Systems.
What would settle it is the permanent financing. If Rocket Lab prices notes or a term loan well inside 8.0%, or funds more of the price with equity, the arithmetic above improves and the deal is better than these numbers make it. If the bridge is still the bridge when Iridium closes, the first year of "positive free cash flow" is roughly $30 million on a $3.6 billion borrowing.
The bridge facility's size, 364-day term, approximately 8.0% effective rate, $285,669 thousand and $141,357 thousand of pro forma interest and $4.55 million sensitivity are from Rocket Lab's merger proxy statement/prospectus of 26 August 2026. The equity programme's size, the $1,055,630,173 already sold and the replacement language are from the prospectus supplement of 13 August 2026; the 598,350,482 share count is the 10 August quarterly report's cover. Rocket Lab's segment revenue is from the same quarterly report. Iridium's cash flow, capital expenditure and net interest are from its own quarterly report for the period; its pro forma free cash flow guidance is a company-defined measure from its 2026 outlook. The rating, target and analyst commentary are press-reported, not a note we hold. Every subtraction, per-share and percentage figure here is ours, and the interest add-back is an approximation of cash interest.
